ArticleNature medicine2023

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.

Sham Mailankody et al.PubMed ↗Publisher ↗

No numbers read from the abstract.